Neonatal Drug Therapy Manual


Disclaimer: Official controlled document is the CHEO and Ottawa Hospital online copy. It is the responsibility of user to ensure that any paper copy version is the same as the online version before use.

Alternate Name(s): 
Original Date: 
March 1993
Revised Date: 
August 2022
  • Pulmonary edema/congestive heart failure
  • As adjunctive therapy for BPD
  • IV direct: over 5 minutes (maximum: 1 mg/kg/dose)
  • IV intermittent infusion: over 15 - 30 minutes
  • IV continuous infusion
  • PO
  • IV:
    • IV direct / IV intermittent infusion:
      • 1 - 2 mg/kg/dose Q12 - 24H
      • ** Follow above administration directives for IV administration**
    • IV continuous infusion: (rarely used)
      • 0.05 mg/kg/hr ; titrate dose to clinical effect
  • PO:
    • 1 - 2 mg/kg/dose Q12 - 24H
Side Effects: 
  • CVS: hypotension, cardiac arrhythmias (rare)
  • Endocrine and metabolic: hyperglycemia, hypocalcemia, hypokalemia, hyponatremia, hypomagnesemia, metabolic alkalosis
  • Otic: potentially ototoxic, especially with concomitant aminoglycosides
  • Renal: hypercalciuria, interstitial nephritis, nephrocalcinosis


Parameters to Monitor: 
  • Serum electrolytes, serum creatinine
  • Weight, urine output
  • BP
  • HR
Reconstitution and Stability: 


IV direct/ IV intermittent infusion/ IV continuous infusion

  • Furosemide 10 mg/mL
    • Take 1 mL (10 mg) and add to 9 mL of 0.9% NaCl
    • Final concentration: 1 mg/mL


IV direct/ IV intermittent infusion

  • Furosemide 10 mg/mL
    • Take 1 mL (10 mg) and add to 9 mL of 0.9% NaCl
    • Final concentration: 1 mg/mL

Continuous infusion

  • Furosemide 10 mg/mL
    • Take 1 mL (10 mg) and add to 19 mL of D5W
    • Final concentration: 0.5 mg/mL

- Solutions Compatible: D5W, D10W, 0.9 % NaCl, dextrose-saline combinations

- Y-site Compatible: calcium gluconate, epinephrine, fentanyl, heparin, KCl up to 40 mmol/L, morphine, SMOF, TPN

Incompatible: dobutamine, dopamine, fluconazole, gentamicin, midazolam, vancomycin

  • Do not use if IV solution is yellow

-American Society of Health-System Pharmacists.  Handbook on Injectable Drugs. 19th Edition. Bethesda: American Society of Health-System Pharmacists; 2017



The information contained on this website is provided for informational purposes only, as a guide to assist physicians, nurses and other healthcare providers in deciding on the appropriate care required for a particular patient. At all times, physicians, nurses and other healthcare providers must exercise their independent clinical judgment, based on their knowledge, training and experience, taking into account the specific facts and circumstances of each patient, when deciding on the appropriate course of investigation and/or treatment to recommend in a particular clinical situation.

CHEO has made every effort to ensure that the information contained on this website is as current and accurate as possible. However, changes can occur due to ongoing research and the constant influx of new information. Where possible, hospitals and healthcare practitioners should verify the information before acting on it.

Reliance on any information in this website is at the user's own risk. CHEO is not responsible or liable for any harm, loss or other consequences from the use or misuse of the information on this website.